BridgeBio Pharma (FRA:2CL) Tax Rate % : -0.43% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. BridgeBio Pharma's Tax Expense for the three months ended in Dec. 2024 was €1.1 Mil. BridgeBio Pharma's Pre-Tax Income for the three months ended in Dec. 2024 was €-254.3 Mil. Therefore, BridgeBio Pharma's Tax Rate % for the quarter that ended in Dec. 2024 was -0.43%.

BridgeBio Pharma Tax Rate % Historical Data

The historical data trend for BridgeBio Pharma's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Tax Rate % Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Rate %

Get a 7-Day Free Trial

-0.21

BridgeBio Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Rate %	Get a 7-Day Free Trial															-	-	-	-	-0.43

BridgeBio Pharma Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

BridgeBio Pharma's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2024 )	/	Pre-Tax Income (A: Dec. 2024 )
	=	1.101	/	-517.795
	=	-0.21 %

BridgeBio Pharma's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as

Tax Rate %	=	Tax Expense (Q: Dec. 2024 )	/	Pre-Tax Income (Q: Dec. 2024 )
	=	1.101	/	-254.255
	=	-0.43 %

BridgeBio Pharma Tax Rate % Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

BBIO:USA 2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines